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Background 
Most cases of abnormal uterine bleeding (AUB) could potentially be managed in primary care but 
lack of access to endometrial sampling leads to avoidable referrals to hospital to rule out 
endometrial hyperplasia and cancer.  
  
Aims 
To design and evaluate a pilot service for primary care endometrial sampling (PCES). 
 
Design 
Retrospective analysis of data from two service evaluations. 
 
Setting 
General practices and the gynaecology department in a large city in the United Kingdom. 
 
Methods 
 ? ? dŽ ĚĞƐŝŐŶ ƚŚĞ ŶĞǁ ƐĞƌǀŝĐĞ ǁĞ ŝĚĞŶƚŝĨŝĞĚ Ăůů ƚŚĞ ĞŶĚŽŵĞƚƌŝĂů ƐĂŵƉůĞƐ ƚĂŬĞŶ ŝŶ ƚŚĞ ĐŝƚǇ ?Ɛ
gynaecology department in 2012/13 and estimated the proportion of these with AUB that would be 
suitable for PCES.  2) To evaluate the new PCES service we analysed data from the first year of 
activity. 
 
Results 
1) 1894 endometrial samples were taken in hospital in 2012/13.  An estimated 424 (22.4%) of these 
were from patients with AUB who fitted the criteria for PCES.  2) In the first year of the PCES service 
108 samples were taken by GPs.  Initial management of these patients was exclusively in primary 
care in 97.2% (104/108), most patients were treated with Mirena IUS (79/109; 73.1%) and there 
were no cases of hyperplasia or cancer.   
 
Conclusions 
Most pre-menopausal patients with AUB could potentially be managed in primary care without 
referral to hospital if ES was made available to appropriately trained and supported GPs.  However, 
ƚŚŝƐƐƚƵĚǇǁĂƐůŝŵŝƚĞĚďǇŝƚ ?ƐƌĞƚƌŽƐƉĞĐƚŝǀĞŶŽŶ-interventional design and more research is required 
to demonstrate safety and cost-effectiveness.   
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Key Message Points 
 
Primary care is a crucial part of the care pathway for patients with abnormal uterine bleeding. 
 
In the first instance, the majority of patients with AUB can be managed exclusively in primary care 
without referral to hospital. 
 
Primary care management of AUB may be cost effective but an economic model of the care pathway 
is required to make accurate comparisons between primary care and secondary care. 
 
 
  
3 
 
Introduction 
Abnormal uterine bleeding (AUB) affects 14-25% of women of reproductive age (1) (2) and one in 20 
women aged 30-49 consults a GP for AUB each year (3).  Most cases of AUB could potentially be 
managed in primary care without referral to hospital.  Careful history and examination is required to 
diagnose AUB by excluding other causes of abnormal vaginal bleeding such as vaginal pathology, 
cervical pathology and pregnancy (4) (5) ?hŝƐĂƐǇŶĚƌŽŵĞĚĞĨŝŶĞĚĂƐ ?ďůĞĞĚŝŶŐĨƌŽŵƚŚĞƵƚĞƌŝŶĞ
corpus that is abnormal in volume, regularity and/or timing that has been present for the majority of 
ƚŚĞůĂƐƚƐŝǆŵŽŶƚŚƐ ?(5) (irregular bleeding associated with hormonal contraception is often referred 
to as breakthrough bleeding).  This definition of AUB includes heavy menstrual bleeding (HMB) (6) 
and prolonged vaginal bleeding and overlaps with the term unscheduled vaginal bleeding, which is 
bleeding that occurs outside the normal menstrual period (or the regular withdrawal bleed 
associated with oral contraception) (7) i.e. irregular bleeding, inter-menstrual bleeding (IMB), post-
coital bleeding (PCB).  Dysfunctional uterine bleeding (DUB) is AUB in the absence of organic disease 
(8) and is the most common cause of menstrual complaints (4) especially towards the end of 
reproductive life (9) (10). 
 
The causes of AUB can be summarised using the PALM-COEIN acronym: polyps, adenomyosis, 
leiomyoma/fibroids, malignancy (and hyperplasia), coagulopathy, ovulatory disorders, endometrial, 
iatrogenic and not otherwise classified (5).  Endometrial cancer is the most common gynaecological 
malignancy in the Western world and rates of endometrial cancer are rising with the increasing 
prevalence of obesity and diabetes (11).  Most women with endometrial cancer are post-
menopausal, the incidence rises steeply with age after 45 (7) with the peak incidence over 55 years.  
However, endometrial cancer can occur in young women.  7% of women with endometrial cancer 
are under 50 years of age and 2-5% are under 40 years of age (6). 
 
Ultrasound scans (USS), which are readily available to GPs in the UK, cannot exclude the presence of 
endometrial atypical hyperplasia or malignancy.  In pre-menopausal women, none of the symptoms 
of AUB are in themselves criteria for urgent referral for suspected cancer (12) but national guidelines 
in the UK recommend that endometrial sampling should be performed for AUB in women >40 (13) 
(14) or >45 (6) to exclude atypical hyperplasia and cancer.  It is not specified if ES should be 
performed in primary care or secondary care.  Despite being a safe and relatively simple 
investigation ES has not traditionally be undertaken in primary care in the UK.  A recent study looked 
at diagnostic strategies for management of AUB and concluded that hysteroscopy with or without ES 
was cost-effective but this was based on a secondary care population and included patients with 
post-menopausal bleeding (15).  Local GPs felt that primary care ES may be a safe and cost effective 
way of managing AUB without referral to hospital.  A new pilot primary care endometrial sampling 
(PCES) service was set-up to facilitate primary care management of AUB.  In this paper we present 
the results of two service evaluations which were used to plan and evaluate the new service.    
 
Methods 
 
Context 
Sheffield is a large city in the United Kingdom with a single Clinical Commissioning Group (CCG).  
CCGs are clinically led statutory National Health Service (NHS) bodies responsible for the planning 
and commissioning of healthcare services for their local area.  Sheffield has a population of 451,100 
adults (551,756 adults and children) (16) and is served by a single acute adult hospital trust (Sheffield 
Teaching Hospitals NHS Foundation Trust) (STH) which includes a specialised gynaecology 
department.  General Practice (GP) is provided in the city by 88 GP partnerships and 113 GP 
practices (GP partnerships often have more than one building/practice).  The total of the registered 
list size for all the practices in Sheffield is 580,263. 
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The Clinical Guideline 
A PCES clinical guideline was drawn-up as part of preparations for the proposed pilot.  AUB was 
defined as heavy menstrual bleeding, irregular bleeding and/or change in bleeding pattern.  The 
ŝŶĐůƵƐŝŽŶ ĐƌŝƚĞƌŝĂ ǁĞƌĞ h ŝŶ ǁŽŵĞŶ A? ? ? ǇĞĂƌƐ ŽůĚ Žƌ A? ? ? ǁŝƚŚ ƌŝƐŬ ĨĂĐƚŽƌƐ  ?ŽďĞƐŝƚǇ ? ƉŽůǇĐǇƐƚŝĐ
ovarian syndrome, diabetes mellitus, tamoxifen use, hereditary nonpolyposis colorectal cancer).  
Exclusion criteria were: post-menopausal bleeding, post-coital bleeding, inter-menstrual bleeding, 
active infection, pregnancy.  The guideline specified full clinical assessment including examination 
and USS for all patients.  The full clinical guideline is available as additional online content (See 
Supplementary 1).  
 
Hospital Service Evaluation 
We undertook a service evaluation at STH to establish the number of endometrial samples 
undertaken each year, the proportion of these with AUB that would be suitable for PCES, and the 
clinical characteristics of the cohort.  We requested the following data from the histopathology 
laboratory 1) the total number of samples taken in 2012/13 and 2) histopathology reports for all 
endometrial samples taken during a sample month.  A data collection tool was created by JMD and 
MEC which was used to extract relevant information from a combination of sources: histopathology 
request forms and reports, USS request forms and reports and medical records.  Data extracted 
were: age, indication for biopsy, AUB which fits the criteria for PCES, endometrial biopsy result and 
initial management plan.  All data was extracted by MEC and borderline cases were discussed with 
JMD. 
 
Calculation of Costs 
 
Secondary Care Costs 
We used Secondary Uses Service (SUS) data from Hospital Episode Statistics (HES) (17) and reviewed 
clinical notes to define the care pathway and tariff for those patients with AUB identified in he 
hospital service evaluation.  STH supplied Yorkshire and Humber Commissioning Support Unit 
(YHCSU) with the NHS numbers of patients identified from the hospital service evaluation as suitable 
for the LCS.  The data were processed by the DMIC (Data Management and Integration Centre) of 
YHCSU.  The processing was carried out by using a pseudonymised data set.  Data processing and 
data sharing agreements were already in place to support the process which comply with data 
protection legislation and Information Governance requirements.  The only data released to the 
study team was fully pseudonymised and identified only by the research ID number.  For each 
suitable patient the SUS database was searched.  We searched using NHS number for outpatient 
attendances six months before and twelve months after the sample month and filtered by speciality 
codes 502 (Gynaecology) and 503 (Gynaecological Oncology).  This allowed identification, on a case-
by-case basis, of procedure codes, number of outpatient attendances, HRG (Health Resources 
Group) codes and the tariff per attendance.  A second analysis of CCG-level anonymised data was 
undertaken for gynaecology referrals in 2013/14 with relevant HRG codes.  The data from these two 
sources, combined with the clinical opinion of MEC and JMD on the usual care pathway, were 
discussed by the costs analysis group (JMD, SA, DM, RS, AE) and a consensus view on the usual 
patient pathway and tariff for a simple case of AUB was determined.  We were not able to check 
with the provider (STH) if the correct procedure code was applied, only which code was actually 
applied.  The cost of USS in primary care and secondary care was not included because this was part 
of routine care before the LCS ĂŶĚƐŚŽƵůĚŶ ?ƚŚĂǀĞĚŝĨĨĞƌĞĚďĞƚǁeen the two groups. 
 
Primary Care Costs 
The costs of consumables and histopathology services for PCES were established from commercial 
suppliers and the histopathology laboratory at STH.  These costs were already included in the tariff 
price for patients managed in secondary care but needed calculating separately for patients 
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managed in primary care.  The basic price for providing a histopathology report for an ES is £55.67, 
but additional immunohistochemistry tests are required for some samples which cost around £30 
each (as many as ten of these may be necessary in some cases).   If 1/200 endometrial samples 
actual cost £350 then the average cost of each sample is £57.  GP practices were paid £40 for each 
sample taken.  The total average cost to the CCG for each PCES undertaken was therefore £97.  
Additional costs to the GP practice were: speculum (£0.84), tenaculum (£4.26), Instillagel (£1.62) and 
endometrial sampler (£1.08). 
 
Primary Care Endometrial Sampling Service Evaluation 
Once the hospital service evaluation was completed and the business case was approved by the 
CCG, the primary care endometrial sampling (PCES) service was set-up as a locally commissioned 
service (LCS) (a contract between the CCG and individual GP practices).  GPs who wished to provide 
the service were required to hold the DFSRH plus the Letter of Competence for Intra-Uterine 
Techniques.  In addition, they were required to attend a two-hour training session led by MEC which 
outlined the clinical guideline (available in full as additional online content) which was drawn-up by 
JMD and MEC based on feedback from local clinicians and key stakeholders.  Endometrial sample 
results taken as part of the LCS were processed by the laboratory in the same way as samples taken 
in secondary care and the result was returned to the requesting GP.  GP practices were required to 
complete a service evaluation form for each sample completed which was submitted to the CCG.  
The data from each service evaluation form were extracted and entered into an SPSS database.  We 
used standard descriptive statistics to analyse the data.   
 
Results 
 
Hospital Service Evaluation  
There were 1894 endometrial samples processed in the histopathology laboratory in the financial 
year 2012/13.  111 were taken in the sample month, 11 were excluded (these were incorrectly 
labelled as ES e.g. sample of peritoneal endometriosis) which left a total of 100 cases where a full set 
of data were extracted (we present the results using a denominator or 111 so that percentages 
generated can be applied to the total group of 1894).  The most common indications for endometrial 
samples taken in hospital were heavy menstrual bleeding (18.0%, 20/111), irregular menstrual 
bleeding (9.9%, 11/111), change in bleeding pattern (0.9%, 1/111), inter-menstrual bleeding (7.2%, 
8/111), post-menopausal bleeding (41.4%, 46/111) and other (18.0%, 20/111).    There were 25/111 
(22.4%) samples from patients with AUB who fitted the criteria for PCES. 
 
Of those with AUB that fitted the criteria for PCES, the mean age was 46 years (SD 6.15), 16/25 (64%) 
were over 45 years and 9/25 (36%) were under 45.  The most numerically important indications 
were heavy menstrual bleeding 12/29 (38%) and irregular bleeding 9/29 (31%) (note that patients 
may have more than one indication hence the denominator of 29).  The majority of ES results were 
normal and there were no cases of endometrial cancer; see Table 1.  The initial management plan 
for these patients is shown in Table 2. 
 
The usual care pathway for a patient with uncomplicated AUB after referral to hospital begins with a 
gynaecology outpatient clinic appointment.  After clinical assessment, USS (which may be 
undertaken in primary or secondary care) and endometrial sampling, most patients are discharged 
from the clinic with a plan to write to the GP and patient with the histology result.  A small 
proportion of these patients, estimated at 20%, are seen in a follow-up outpatient clinic.  STH 
routinely used the procedure code (OPCS) Q181 (diagnostic endoscopic examination of the uterus) 
for patients with AUB who underwent endometrial sampling.  The HRG (Health Resources Group) 
code for a new outpatient gynaecology clinic appointment, plus the procedure code (OPCS) Q181 
(diagnostic endoscopic examination of the uterus) is MA21Z which, based on the 2013/14 tariff, 
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generates a price of £486.  A single follow-up outpatient gynaecology clinic appointment generates a 
tariff of £82/£91 (mean of £87 used for subsequent calculations) for gynaecology/gynaecological 
oncology and so the average patient pathway generates a bill to the CCG of £503 (£486 + (0.2 x 
£87)). 
 
Primary Care Service Evaluation 
Of the GP partnerships in Sheffield 34/88 (39%) confirmed that they would like to provide the LCS 
starting from April 2014.  By the end of March 2015, 19/88 had undertaken at least one endometrial 
sample as part of the LCS.  The total of the registered list size for these 19 GP partnerships is 157,423 
(27.1% of the Sheffield total list size).  There were a total of 108 primary care endometrial samples 
were taken in the 12 months between April 2014 and March 2015. 
 
The most frequent indications for the samples were HMB 82/108 (75.9%), irregular bleeding 31/108 
(28.7%) and change in bleeding pattern 34/108 (31.5%).   The median age of the patients was 46 
(range 25-58), 76/108 (70.4%) were over 45 years old and 32/108 (29.6%) were under 45.  Of the 
32/108 patients who were under 45 years old, 31/32 (97%) had risk factors for endometrial 
hyperplasia/cancer.  The most common risk factors were obesity 19/32 (59.4%), PCOS 3/32 (9.4%) 
and diabetes mellitus 3/32 (6.3%).  The majority of patients 98/108 (92.5%) had an USS.  Of these 
48/98 (44.9%) ǁŽŵĞŶ ŚĂĚ ŶŽƌŵĂů ƐĐĂŶƐ  ? ?ŶŽ ĂďŶŽƌŵĂůŝƚǇ ĚĞƚĞĐƚĞĚ ? ?, fibroids were detected in 
40/98 (37.4%) and 10/98 (10.2%) had other abnormalities such as adenomyosis and simple ovarian 
cysts.  The majority of ES results were normal (see Table 1), there were no cases of endometrial 
cancer, 2/108 (1.9%) samples were inadequate and there were no failed procedures (although this 
ĚĂƚĂǁĂƐŶ ?ƚƐƉĞĐŝĨŝĐĂůůǇĐŽůůĞĐƚĞĚ ?.
 
Initial management was exclusively in primary care in 104/108 (97.2%), 3/108 (2.8%) women were 
referred routinely to gynaecology and no patients were referred to the fast track service for 
ƐƵƐƉĞĐƚĞĚĐĂŶĐĞƌ ? ?ƚǁŽǁĞĞŬǁĂŝƚ ? ?.  Formal advice on management from the hospital gynaecology 
department or the gynaecology triage service was taken in 7/67 (6.5%) cases.  The most common 
primary care management plans were Mirena coil 79/108 (73.1%), oral medication 13/108 (12.0%) 
and continued observation without treatment 16/108 (14.8%). 
 
Discussion 
Our results demonstrate that GPs are able to assess and manage most cases of AUB in the first 
instance without referral to hospital and without advice from specialists.  The cost of managing each 
case in primary care was £97 and the average hospital cost for each case of AUB was £503.  
Feedback from GPs after the first year of the pilot was that £40 was insufficient and the fee was 
increased to £75 but even including this increase, the LCS generates a cost saving of 74% per case.  
The primary care costs that we calculated were based on the fee paid by the CCG to the GP practice 
per ES not the actual amount of time spent by the GP, and other members of the primary care team, 
managing each case.  There is no formula for calculating the costs of activity in general practice 
based on time aliquots, appointment duration or type of appointment e.g. with a GP or a nurse.  The 
hospital cost per case of AUB of £503 was generated by STH by applying the procedure code Q181 
(diagnostic endoscopic examination of the uterus) despite the fact that none of these patients had 
undergone hysteroscopy.  We were unable to establish if this code was applied deliberately or 
erroneously by STH and we are not aware of any rules used by hospital coders to guide them in 
correctly applying procedure codes.  A proper health economic model is required to draw more 
accurate and robust conclusions but our data show that PCES may be a cost-effective strategy. 
 
The majority of ES results in both the primary care and hospital cohorts were normal and there were 
no cases of endometrial cancer.  This raises the question of whether endometrial sampling is 
necessary in all cases of AUB; current national guidance is ambiguous on this issue.  Further research 
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on the epidemiology of AUB in primary care populations especially the predictive value of risk 
factors and individual symptoms for hyperplasia/cancer would allow risk stratification of patients 
and may allow identify groups of patients sampling in the >45 age group that can be managed 
without endometrial sampling.  The ES results and initial management plans were comparable in the 
GP and hospital cohorts.  The only major difference was the use of Mirena IUS which was much 
more common in primary care (79/108; 73.1%) than in hospital (7/25; 28%).  Mirena IUS is an 
effective treatment and is the first line treatment in the UK (18) (19) (20) (6).  We do not have data 
on what percentage of these patients were not satisfied with the initial treatment and eventually 
required referral to gynaecology.   
 
Our data show that 426 of the patients who had an ES in hospital in 2012/13 (22.5% x 1894) had AUB 
which could have been managed in primary care  ?ƚŚĞ ?ĂŶŶƵĂůĚĞŵĂŶĚ ? for PCES).  In the first year of 
the pilot LCS, 25.4% (108/426) of the annual demand was met by GP practices.  The 19 practices that 
actually delivered the service in the pilot year covered 27.1% of the Sheffield list size.  So the 
practices that delivered the service seemed to meet the pro-rata needs of their population.  The 
challenge of meeting 100% of the annual demand for PCES is to extend the service to patients 
registered with practices that do not currently deliver the service.  There are a number of likely 
barriers to practices offering the service to their own patients: inadequate remuneration, lack of 
appropriately qualified staff, workload, medico-legal concerns, and justifying setting-up a service for 
a relatively small number of patients per practice per year.  These factors probably explain the drop-
out from those practices that signed-up for the LCS and those that actually delivered it.  Training 
requirements for ES mean that many practices may not have clinical staff qualified to deliver the 
service.  Innovative methods of primary care service delivery such as inter-practice referral or 
primary care specialist providers may be necessary to deliver this service to the entire population of 
the city and there is only limited evidence that this type of working at scale can be effective (21) (22). 
 
Limitations 
The retrospective design of our study was the major limitation, some variables such as precise 
symptoms are likely to have been incompletely recorded in the clinical notes, we found that data for 
some variables was missing in some cases and we did not collected data on failed procedures.  A 
prospective study where these variables could have been specifically enquired about directly with 
the patient would have been more accurate.  A prospective design would also allow collection of 
follow-up data to draw stronger conclusions on safety and to quantify adverse outcomes.  The low 
prevalence of cancer and hyperplasia in our data confirm that the risk of these conditions is low but 
we do not have data on the potential of missed diagnoses in our cohorts.  GPs have a responsibility 
to report significant events (23) but there was no formal requirement for these to be reported to the 
CCG during the study period (this has subsequently been changed).  We did not collect any long-term 
follow-up data and therefore we cannot draw firm conclusions about the outcomes of our patients or 
the safety of the service.  There are limitations in our method of estimating and comparing costs for 
the pathway in primary care and in secondary care.  Further research using a health economic model, 
a larger sample size and a prospective design would provide stronger evidence for the conclusions in 
this paper.   
 
Conclusions 
Most pre-menopausal patients with AUB could potentially be assessed and managed in primary care 
without referral to hospital if ES was made available to appropriately trained and supported GPs.  
,ŽǁĞǀĞƌ ?ƚŚŝƐƐƚƵĚǇǁĂƐůŝŵŝƚĞĚďǇŝƚ ?ƐƌĞƚƌŽƐƉĞĐƚŝǀĞŶŽŶ-interventional design and more research is 
required to demonstrate safety and cost-effectiveness.   
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Category Hospital Results GP Results Description 
 
1 23/25 (92%) 105/108 (97.2%) Secretory changes, consistent/inconsistent with time of cycle.    
Proliferative changes, consistent/inconsistent with time of cycle.   
Inactive endometrium. 
2 1/25 (4%) 2/108 (1.9%) Inadequate as no endometrial tissue in the sample 
 
 
3 0/25 (0%) 1/108 (0.9%) Simple hyperplasia 
 
 
4 1/25 (4%) 0/108 (0%) Complex hyperplasia without atypia.   
Complex hyperplasia with atypia/Endometrial intraepithelial neoplasia. 
 
5 0/25 (0%) 0/108 (0%) Endometriod endometrial adenocarcinoma or other endometrial malignancy. 
 
 
 
Table 1.  Histopathology results from endometrial samples in the hospital cohort and the GP cohort.   
 
 
  
10 
 
Management General Practice  Hospital  
No treatment 16/108 (14.8%) 4/25 (17%) 
Oral medication 13/108 (12.0%) 6/25 (24%) 
Mirena IUS 79/108 (73.1%) 7/25 (28%) 
Uterine artery embolisation N/A 0/25 (00%) 
Hysteroscopic procedure N/A 2/25 (08%) 
Endometrial ablation N/A 2/25 (08%) 
Hysterectomy N/A 0/25 (00%) 
Myomectomy N/A 0/25 (00%) 
Other/missing N/A 4/25 (16%) 
 
Table 2.  The initial management of patients with AUB in the hospital cohort and in the GP cohort.   
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